VRTX Q2 2024 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.6B+6.1% YoY

Gross Profit

$2.3B85.9% margin

Operating Income

-$3.5B-132.9% margin

Net Income

-$3.6B-135.8% margin

EPS (Diluted)

$-13.92

QoQ Revenue Growth

-1.5%

Cash Flow

Operating Cash Flow

-$3.8B

Free Cash Flow

-$3.8B

Stock-Based Comp.

$154M

Balance Sheet

Total Assets

$20.1B

Total Liabilities

$5.4B

Stockholders' Equity

$14.8B

Cash & Equivalents

$4.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.6B	$2.5B	+6.1%
Gross Profit	$2.3B	$2.2B	+4.1%
Operating Income	-$3.5B	$1.0B	-442.4%
Net Income	-$3.6B	$916M	-492.4%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.4B100%

Geographic Segments

UNITED STATES

$1.6B61%

Europe

$807M30%

Other, Non U.S.

$225M8%